Zacks Investment Research upgraded shares of Avinger (NASDAQ:AVGR) from a sell rating to a hold rating in a research report released on Tuesday.
According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “
AVGR opened at $1.15 on Tuesday. The firm has a market cap of $15.25 million, a price-to-earnings ratio of -0.02 and a beta of 0.86. Avinger has a 52 week low of $0.95 and a 52 week high of $16.40.
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.